Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
A biopharmaceutical company will know this year whether an antibody produced using a unique technique can prevent chronic migraines.
Polymers that mimic the body’s natural defenses could be a new class of inexpensive therapeutics.
A number of dual-action antibodies are in clinical trials for fighting cancer.